Inspire Medical Systems, Inc. (INSP)
Pre-market:
| Previous close | 205.00 |
| Open | 207.01 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 800 |
| Day's range | 205.24 - 214.95 |
| 52-week range | 123.00 - 257.40 |
| Volume | |
| Avg. volume | 657,418 |
| Market cap | 6.41B |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | 1,023.48 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid
- GlobeNewswire
Inspire Medical Systems, Inc. to Present at Upcoming Investor Conferences
MINNEAPOLIS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024. Inspire is scheduled to present at th
- GlobeNewswire
Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program
MINNEAPOLIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that its Board of Directors has authorized the repurchase of up to $150.0 million of the company’s outstanding shares of common stock. “I am pleased to announce our intention to purchase up to $15
